P-024. Lymphocyte subset populations are altered in adult patients with GH deficiency. Effects of long-term GH replacement therapy

A. Frasoldati, M. Zini, L. Albertazzi, A. Vottero, L. Ghizzoni, S. Bernasconi, R. Valcavi

Research output: Contribution to journalArticle

Abstract

Lymphocyte subset populations were studied in 24 adult patients (13 M, 11 F; age 39.8±13) with GH deficiency (= GHD), before and during GH replacement therapy (Genotropin® Pharmacia, 0.035 IU/Kg/day s.c.), and in 24 sex- and age-matched healthy subjects. According to a double-blind schedule, GHD patient received GH/placebo for 6 months. During the following 6 months, GH was given to all patients. A subgroup of 10 GHD patients was kept on GH therapy for further 12 months. Results: (1) GHD patients showed decreased CD2+ (total lymphocytes), CD3+, (T lymphocytes), CD4+ (T helper), CD16+ (NK) cell levels, and increased CD19+ (8 lymphocytes) cell levels. (2) After 12 months, changes in CD2+, CD3+, CD4+ cell levels were reversed, whereas CD8+ (T suppressor) cell levels raised above control values. (3) The effects of GH therapy on lymphocyte subsets were maintained after 24 months treatment, with the exception of CD19+ cell levels which were reduced. IGF-1 (U/dl) CD2+ (%) CD3+ (%) CD4+ (%) CD8 (%) CD16 (%) CD19 (%) Control Subjects 145±48 85.0±7.4 74.5±6.8 48.±6.4 20.6±7.9 7.3±4.1 6.4±3.7 GHD patients 27±18 a 77.4±7.0 a 68.7±7.3 a 42.2±8.3 a 22.5±8.0 2.4±3.03 10.7±5.4 GHD p. after 12 months 110±61 84.9±8.2 b 78.7±8.2 b 48.9±9.4 b 26.1±9.2 b 3.2±3.3 9.5±7.6 GHD p. after 24 months 124±79 90.0±4.2 b 82.3±4.9 52.9±9.1 b 26.7±9.5 c 3.9±4.0 3.1±1.4 b apbp

Original languageEnglish
Pages (from-to)45
Number of pages1
JournalEndocrinology and Metabolism, Supplement
Volume4
Issue numberA
Publication statusPublished - 1997

Fingerprint

Lymphocyte Subsets
Population
Lymphocytes
Therapeutics
Human Growth Hormone
Insulin-Like Growth Factor I
Natural Killer Cells
Appointments and Schedules
Healthy Volunteers
Placebos

ASJC Scopus subject areas

  • Endocrinology

Cite this

P-024. Lymphocyte subset populations are altered in adult patients with GH deficiency. Effects of long-term GH replacement therapy. / Frasoldati, A.; Zini, M.; Albertazzi, L.; Vottero, A.; Ghizzoni, L.; Bernasconi, S.; Valcavi, R.

In: Endocrinology and Metabolism, Supplement, Vol. 4, No. A, 1997, p. 45.

Research output: Contribution to journalArticle

Frasoldati, A. ; Zini, M. ; Albertazzi, L. ; Vottero, A. ; Ghizzoni, L. ; Bernasconi, S. ; Valcavi, R. / P-024. Lymphocyte subset populations are altered in adult patients with GH deficiency. Effects of long-term GH replacement therapy. In: Endocrinology and Metabolism, Supplement. 1997 ; Vol. 4, No. A. pp. 45.
@article{5185b6a6f98041a0aa8a786d9ac95e96,
title = "P-024. Lymphocyte subset populations are altered in adult patients with GH deficiency. Effects of long-term GH replacement therapy",
abstract = "Lymphocyte subset populations were studied in 24 adult patients (13 M, 11 F; age 39.8±13) with GH deficiency (= GHD), before and during GH replacement therapy (Genotropin{\circledR} Pharmacia, 0.035 IU/Kg/day s.c.), and in 24 sex- and age-matched healthy subjects. According to a double-blind schedule, GHD patient received GH/placebo for 6 months. During the following 6 months, GH was given to all patients. A subgroup of 10 GHD patients was kept on GH therapy for further 12 months. Results: (1) GHD patients showed decreased CD2+ (total lymphocytes), CD3+, (T lymphocytes), CD4+ (T helper), CD16+ (NK) cell levels, and increased CD19+ (8 lymphocytes) cell levels. (2) After 12 months, changes in CD2+, CD3+, CD4+ cell levels were reversed, whereas CD8+ (T suppressor) cell levels raised above control values. (3) The effects of GH therapy on lymphocyte subsets were maintained after 24 months treatment, with the exception of CD19+ cell levels which were reduced. IGF-1 (U/dl) CD2+ ({\%}) CD3+ ({\%}) CD4+ ({\%}) CD8 ({\%}) CD16 ({\%}) CD19 ({\%}) Control Subjects 145±48 85.0±7.4 74.5±6.8 48.±6.4 20.6±7.9 7.3±4.1 6.4±3.7 GHD patients 27±18 a 77.4±7.0 a 68.7±7.3 a 42.2±8.3 a 22.5±8.0 2.4±3.03 10.7±5.4 GHD p. after 12 months 110±61 84.9±8.2 b 78.7±8.2 b 48.9±9.4 b 26.1±9.2 b 3.2±3.3 9.5±7.6 GHD p. after 24 months 124±79 90.0±4.2 b 82.3±4.9 52.9±9.1 b 26.7±9.5 c 3.9±4.0 3.1±1.4 b apbp",
author = "A. Frasoldati and M. Zini and L. Albertazzi and A. Vottero and L. Ghizzoni and S. Bernasconi and R. Valcavi",
year = "1997",
language = "English",
volume = "4",
pages = "45",
journal = "Endocrinology and Metabolism, Supplement",
issn = "1074-939X",
publisher = "Bailliere Tindall Ltd",
number = "A",

}

TY - JOUR

T1 - P-024. Lymphocyte subset populations are altered in adult patients with GH deficiency. Effects of long-term GH replacement therapy

AU - Frasoldati, A.

AU - Zini, M.

AU - Albertazzi, L.

AU - Vottero, A.

AU - Ghizzoni, L.

AU - Bernasconi, S.

AU - Valcavi, R.

PY - 1997

Y1 - 1997

N2 - Lymphocyte subset populations were studied in 24 adult patients (13 M, 11 F; age 39.8±13) with GH deficiency (= GHD), before and during GH replacement therapy (Genotropin® Pharmacia, 0.035 IU/Kg/day s.c.), and in 24 sex- and age-matched healthy subjects. According to a double-blind schedule, GHD patient received GH/placebo for 6 months. During the following 6 months, GH was given to all patients. A subgroup of 10 GHD patients was kept on GH therapy for further 12 months. Results: (1) GHD patients showed decreased CD2+ (total lymphocytes), CD3+, (T lymphocytes), CD4+ (T helper), CD16+ (NK) cell levels, and increased CD19+ (8 lymphocytes) cell levels. (2) After 12 months, changes in CD2+, CD3+, CD4+ cell levels were reversed, whereas CD8+ (T suppressor) cell levels raised above control values. (3) The effects of GH therapy on lymphocyte subsets were maintained after 24 months treatment, with the exception of CD19+ cell levels which were reduced. IGF-1 (U/dl) CD2+ (%) CD3+ (%) CD4+ (%) CD8 (%) CD16 (%) CD19 (%) Control Subjects 145±48 85.0±7.4 74.5±6.8 48.±6.4 20.6±7.9 7.3±4.1 6.4±3.7 GHD patients 27±18 a 77.4±7.0 a 68.7±7.3 a 42.2±8.3 a 22.5±8.0 2.4±3.03 10.7±5.4 GHD p. after 12 months 110±61 84.9±8.2 b 78.7±8.2 b 48.9±9.4 b 26.1±9.2 b 3.2±3.3 9.5±7.6 GHD p. after 24 months 124±79 90.0±4.2 b 82.3±4.9 52.9±9.1 b 26.7±9.5 c 3.9±4.0 3.1±1.4 b apbp

AB - Lymphocyte subset populations were studied in 24 adult patients (13 M, 11 F; age 39.8±13) with GH deficiency (= GHD), before and during GH replacement therapy (Genotropin® Pharmacia, 0.035 IU/Kg/day s.c.), and in 24 sex- and age-matched healthy subjects. According to a double-blind schedule, GHD patient received GH/placebo for 6 months. During the following 6 months, GH was given to all patients. A subgroup of 10 GHD patients was kept on GH therapy for further 12 months. Results: (1) GHD patients showed decreased CD2+ (total lymphocytes), CD3+, (T lymphocytes), CD4+ (T helper), CD16+ (NK) cell levels, and increased CD19+ (8 lymphocytes) cell levels. (2) After 12 months, changes in CD2+, CD3+, CD4+ cell levels were reversed, whereas CD8+ (T suppressor) cell levels raised above control values. (3) The effects of GH therapy on lymphocyte subsets were maintained after 24 months treatment, with the exception of CD19+ cell levels which were reduced. IGF-1 (U/dl) CD2+ (%) CD3+ (%) CD4+ (%) CD8 (%) CD16 (%) CD19 (%) Control Subjects 145±48 85.0±7.4 74.5±6.8 48.±6.4 20.6±7.9 7.3±4.1 6.4±3.7 GHD patients 27±18 a 77.4±7.0 a 68.7±7.3 a 42.2±8.3 a 22.5±8.0 2.4±3.03 10.7±5.4 GHD p. after 12 months 110±61 84.9±8.2 b 78.7±8.2 b 48.9±9.4 b 26.1±9.2 b 3.2±3.3 9.5±7.6 GHD p. after 24 months 124±79 90.0±4.2 b 82.3±4.9 52.9±9.1 b 26.7±9.5 c 3.9±4.0 3.1±1.4 b apbp

UR - http://www.scopus.com/inward/record.url?scp=33747713272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747713272&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33747713272

VL - 4

SP - 45

JO - Endocrinology and Metabolism, Supplement

JF - Endocrinology and Metabolism, Supplement

SN - 1074-939X

IS - A

ER -